Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Authors: David M. Reid, Jean‐Pierre Devogelaer, Kenneth G. Saag, Christian Roux, Chak-Sing Lau, Jean‐Yves Reginster, P. Papanastasiou, Alberto Ferreira, Florian Hartl, T. Fashola, Peter Mesenbrink, Philip N. Sambrook - The Lancet 2009 cited by 529